Both documents, Guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified body on companion diagnostics and Questions & Answers - Practical arrangements on the companion diagnostics consultation procedure to the European Medicines Agency by notified bodies were updated due to the new Regulation (EC) 2024/568 on fees and charges payable to the EMA (from 1 January 2025). These documents are intended to provide the relevant parties, in particular notified bodies, device manufacturers, and medicinal product applicants, with information on the consultation procedure to the EMA by a notified body on a companion diagnostic (CDx).
What is updated in EMA/198592/2022 Rev.1 and EMA/619893/2022 Rev.1:
In the Guidance on the procedural aspects, the section on fees has been updated, now referring to the applicable EMA webpage as well as to a guide for small and medium-sized enterprises regarding fee reductions. Similar changes have been made in the Q&A document.
What does it mean to you?
Although the consultation procedure is part of the notified body’s conformity assessment of a CDx, EMA/198592/2022 Rev.1 and EMA/619893/2022 Rev.1 are of interest for manufacturers and consultants to understand the initial consultation procedure and possible follow-up consultations in case of substantial changes to the CDx. The fees to be paid are charged to the IVD manufacturer as part of the conformity assessment fee.
关于作者
MSc Biomedical Sciences · Business Unit Manager RA IVD & Representative Services
With over 20 years of experience in the diagnostics industry, Kirsten leads the IVD Regulatory Affairs business unit at QbD Group, guiding regulatory strategy and compliance across all IVDs with a focus on companion diagnostics.
Navigate Regulatory Complexity with Confidence
Navigate complex regulatory landscapes with expert guidance across pharmaceuticals, medical devices, and IVD.
Read more订阅生命科学领域的最新动态
专家观点直达您的收件箱——选择您的兴趣。
绝无垃圾邮件。随时取消订阅。
